Saturday, 28 September 2013

EASD Barcelona 2013

Access to abstracts, eposters and webcasts from (EASD Virtual Meeting)

Friday, 27 September 2013

Advice for people newly diagnosed with Type 2 diabetes

This leaflet is designed to give you some initial advice until you are able to attend a structured education programme. It will help you start to manage your diabetes, whilst continuing to live a full and active life (Diabetes National Specialist Advisory Group - NHS Wales)


Novo Nordisk's diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III (PMLive)


Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes

Our study demonstrates that LDL cholesterol was associated with an increased risk for cardiovascular outcomes in people with type 2 diabetes, independent of other conventional risk factor (Diabetes Research and Clinical Practice)

New data for Novartis drug Lucentis

New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications (Novartis)

Thursday, 26 September 2013

Health Minister launches Diabetes Delivery Plan

The Welsh Health Minister Mark Drakeford has today launched a Delivery Plan for the Welsh NHS to improve diabetes care (Welsh Government)

Wednesday, 25 September 2013

Antidepressant Medication as a Risk Factor for Type 2 Diabetes and Impaired Glucose Regulation

Although evidence exists that antidepressant use may be an independent risk factor for type 2 diabetes, long-term prospective studies of the effects of individual antidepressants rather than class effects are required (Diabetes Care)


Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study)

Treatment with dextrose gel is inexpensive and simple to administer. Dextrose gel should be considered for first-line treatment to manage hypoglycaemia in late preterm and term babies in the first 48 h after birth (The Lancet)

Tuesday, 24 September 2013

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

Linagliptin added to basal insulin therapy significantly improved glycemic control relative to placebo without increasing hypoglycemia or body weight (Diabetes Care)


Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure

In this Review, we discuss representation of drug exposure in pharmacoepidemiological investigations of the connection between diabetes drugs and cancer risk. We identify principles that might improve future research (particularly in observational studies), and consider issues related to reverse causation and detection bias (The Lancet Diabetes & Endocrinology)


Type 2 diabetes: lixisenatide

Evidence summary: new medicine (NICE)

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies

Vipidia (alogliptin) and Fixed-Dose Combinations Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone)


Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes

Two pooled analyses of data from clinical trials in adults with type 2 diabetes, including the elderly with normal renal function to severe renal impairment, found similar incidence of adverse events for linagliptin compared with placebo (Lilly)


The association between dietary patterns and type 2 diabetes: a systematic review and meta-analysis of cohort studies

The results of this systematic review and meta-analysis indicate that dietary patterns may be associated with the risk of type 2 diabetes (Journal of Human Nutrition and Dietetics)

Monday, 23 September 2013

Increased orosomucoid in urine is an independent predictor of cardiovascular and all-cause mortality in patients with type 2 diabetes at 10years of follow-up

UOER is an independent predictor of all-cause and cardiovascular mortality even in normoalbuminuric patients with T2DM at 10years of follow-up (Diabetes and Its Complications)

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study)

Although the primary outcome was not met, at 12 months, alefacept preserved the 4 h C-peptide AUC, lowered insulin use, and reduced hypoglycaemic events, suggesting efficacy. Safety and tolerability were similar in the alefacept and placebo groups. Alefacept could be useful to preserve ß-cell function in patients with new-onset type 1 diabetes (The Lancet Diabetes & Endocrinology)

Sunday, 22 September 2013

Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review

Emerging data suggest that there is an impact of hypoglycaemia on CV function and mechanistic link is multifactorial. Further research will be needed to ascertain the full impact of hypoglycaemia on the CV system and its complications (Cardiovascular Diabetology)

Saturday, 21 September 2013

Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage

As a company with a 90 year history dedicated to diabetes care, research, and education, Novo Nordisk has always put patients first. We would like to respond and set out our position on the recent articles and related commentary on incretins and pancreatic damage (British Medical Journal)

Improvement in ß-Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol

These data indicate that engrafted islet ß-cell mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in ß-cell secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets (Diabetes)

Friday, 20 September 2013

New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults

Aesica unveils a new High Capacity Manufacturing Facility investing £30 million at its Queenborough, UK site (Aesica)

Culturally sensitive patient-centred educational programme for self-management of type 2 diabetes: A randomized controlled trial

This study demonstrates the effectiveness of culturally sensitive, structured, group-based diabetes education in enhancing biomedical and behavioural outcomes in Diabetic patients (Primary Care Diabetes)

Wednesday, 18 September 2013

2-Aminoadipic acid is a biomarker for diabetes risk

In summary, we identified a metabolite biomarker (2-AAA) that predicts the development of diabetes in normoglycemic individuals. Individuals with high plasma 2-AAA concentrations had up to a 4-fold risk of future diabetes (Journal of Clinical Investigation)


All-Cause, Cardiovascular, and Cancer Mortality Rates in Postmenopausal White, Black, Hispanic, and Asian Women With and Without Diabetes in the United States

Within each racial/ethnic subgroup, women with diabetes had an approximately 2–3 times higher risk of all-cause, cardiovascular, and cancer mortality than did those without diabetes (American Journal of Epidemiology)


A systematic review of the experience of older women living and coping with type 2 diabetes

For female patients with diabetes, holistic care and individual psycho-education programmes appear to be facilitate more effective and successful diabetes management. In addition, carer programmes that provide information so that family and friends can support and assist the woman with diabetes are required (International Journal of Nursing Practice)


Changes in time to insulin initiation in type 2 diabetes patients: A retrospective database analysis in Germany and UK (2005–2010)

This real world data shows that the time to insulin therapy has increased in type 2 diabetes patients from 2005 to 2010 (Germany, UK). The average HbA1c values before insulin therapy also slightly increased during this period (Primary Care Diabetes)


Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis

Pooled results suggest that in patients with diabetes, a moderate peri-operative glycemic target (150–200mg/dl [5.6–8.3mmol/l]) is associated with reduction in postoperative mortality and stroke compared with a liberal target (>200mg/dl [11.1mmol/l]), whereas no significant additional benefit was found with more strict glycemic control (<150mg/dl [5.6mmol/l]) (Diabetes Research and Clinical Practice)

Tuesday, 17 September 2013

Depression and Death in Diabetes; 10-Year Follow-Up of All-Cause and Cause-Specific Mortality in a Diabetic Cohort

Our study confirmed a significant positive relationship between depression and mortality in patients with type 2 diabetes (Psychosomatics)


Early Diabetic Nephropathy - A complication of reduced insulin sensitivity in type 1 diabetes

Over 6 years, a higher ISI independently predicts a lower odds of developing microalbuminuria and rapid GFR decline as estimated with cystatin C, suggesting a relationship between insulin sensitivity and early phenotypes of DN (Diabetes Care)

Time Lag of Glucose from Intravascular to Interstitial Compartment in Humans

Physiological delay between blood glucose and interstitial fluid glucose should, therefore, not be an obstacle to sensor accuracy in overnight or fasting state closed loop systems of insulin delivery or open loop therapy assessment for type 1 diabetes (Diabetes)

Monday, 16 September 2013

Diabetes drug reverses Alzheimer’s and could be available in five years

Results from the Alzheimer’s Society-funded study, led by Professor Christian Hölscher who is now at Lancaster University, show that the drug liraglutide might be able to reverse some of the damage caused by Alzheimer’s disease, even in the later stages of the condition (Lancaster University)


Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Linagliptin administered in addition to stable RAAS inhibitors led to a significant reduction in albuminuria in patients with type 2 diabetes and renal dysfunction. This observation was independent of changes in glucose level or SBP (Diabetes Care)


Network-Level Structural Abnormalities of Cerebral Cortex in Type 1 Diabetes Mellitus

The current results provide structural evidence for T1DM-related dysfunctional cortical organization, which specifically underlie the top-down cognitive control of language, memory, and emotion (PLoS ONE)

Friday, 13 September 2013

Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus

Bariatric surgery can induce a significant and sustainable remission and improvement of T2DM and other metabolic risk factors in severely obese patients. Surgical intervention within 5 years of diagnosis is associated with a high rate of long-term remission (Annals of Surgery)


Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

This paper reviews recent advances in basal insulin analogues, including a critical appraisal of the degludec trials (Diabetes/Metabolism Research and Reviews)

Thursday, 12 September 2013

Long-Term Efficacy of Subcutaneous ACTH Gel on Proteinuria, Progression of CKD

This trial of ACTH gel in 14 patients with ACE inhibitor-resistant nephrotic syndrome secondary to advanced diabetic nephropathy showed that 6 months of therapy significantly reduces proteinuria and stabilizes renal function in over half the patients (Journal of Diabetes Research)

Sanofi Provides Update on Lixisenatide New Drug Application in U.S.

Sanofi announce decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S., which included early interim results from the ongoing ELIXA cardiovascular (CV) outcomes study. The company plans to resubmit the NDA in 2015, after completion of the ELIXA CV study (Sanofi Aventis)



Wednesday, 11 September 2013


In a world first, Newcastle scientists are studying the physiological performance of cyclists 1,000 miles away as they tackle a gruelling ride and diabetes at the same time (Newcastle University)
Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)

EDGE demonstrates that in a ‘real-life’ setting, vildagliptin as second oral antihyperglycaemic drugs (OAD) can lower HbA1c to target without well-recognised OAD side effects, more frequently than comparator OADs (International Journal of Clinical Practice)


Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients

Our study demonstrates that PV is closely correlated with diabetes and diabetes has a direct effect on the occurrence and development of BPH (International Urology and Nephrology)

Tuesday, 10 September 2013

Type 1 diabetes: insulin degludec and Type 2 diabetes: insulin degludec

Key points from the evidence (NICE)



Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin

Metformin use was associated with impaired cognitive performance. Vitamin B12 and calcium supplements may alleviate metformin-induced vitamin B12 deficiency and were associated with better cognitive outcomes. Prospective trials are warranted to assess the beneficial effects of vitamin B12 and calcium use on cognition in older people with diabetes who are taking metformin (Diabetes Care)


Preadmission metformin use and mortality among intensive care patients with diabetes

Preadmission metformin use was associated with reduced 30-day mortality among medical and surgical intensive care patients with type 2 diabetes (Critical Care)


Islet autoimmunity in phenotypic type 2 diabetes patients

In this manuscript, the involvement of cell-mediated islet autoimmune disease in the progression of T2D disease and the similarities in islet-specific T-cell reactivity between type 1 diabetes (T1D) and T2D are discussed (Diabetes, Obesity and Metabolism)


Amino acid with promising anti-diabetic effects

New experiments conducted by researchers from the University of Copenhagen show that the amino acid arginine – found in a wide variety of foods such as salmon, eggs and nuts – greatly improves the body’s ability to metabolise glucose original paper (Department of Drug Design and Pharmacology at the University of Copenhagen)


Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins

China’s healthcare sector is growing at an accelerated rate, with healthcare spending projected to grow from $357 billion in 2011 to $1 trillion by 2020

Monday, 9 September 2013

Lixisenatide (Lyxumia®) is accepted for restricted use within NHS Scotland

Lixisenatide reduces glycosylated haemoglobin (HbA1c) and body weight compared with placebo when used in combination with oral antidiabetic drugs or in combination with basal insulin (Scottish Medicines Consortium )


Bid success could change the face of paediatric diabetes healthcare

A highly qualified workforce of healthcare professionals across Europe, trained in the delivery of paediatric diabetes education, could soon be the future thanks to Leeds Metropolitan University's award-winning diabetes enterprise unit, Getting Sorted (Leeds Metropolitan University)



Choice of early treatment regimen and impact on ß-cell preservation in type 2 diabetes

The implication of current data is that early initiation of lifestyle modifications and antihyperglycaemic agents that preserve ß-cell function might reverse or delay progression to T2DM in those with prediabetes. Moreover, improved ß-cell function may confer more durable glucose control and perhaps reduce/delay the incidence of diabetic complications (International Journal of Clinical Practice)


Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes

Empagliflozin provides a tolerable and efficacious strategy to reduce HbA1c in patients with type 2 diabetes who had not previously received drug treatment (The Lancet)


SGLT2 versus DPP4 inhibitors for type 2 diabetes

Presently, choosing between a SGLT2 inhibitor and a DPP4 inhibitor to manage hyperglycaemia in type 2 diabetes is difficult: each pharmacological class has advantages and disadvantages. The clinical results of large, long-term, prospective placebo-controlled trials assessing cardiovascular outcomes, presently in progress with DPP4 inhibitors and SGLT2 inhibitors will help guide clinicians further (The Lancet)


Thursday, 5 September 2013

Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications

Over the lifetime, type 2 diabetes imposes a substantial economic burden on healthcare systems. Effective interventions that prevent or delay type 2 diabetes and diabetic complications might result in substantial long-term savings in healthcare costs (American Journal of Preventive Medicine)




The estimated prevalence of diabetes among a representative sample of Chinese adults was 11.6% and the prevalence of prediabetes was 50.1%.

Wednesday, 4 September 2013

Feedback of personal retinal images appears to have a motivational impact in people with non-proliferative diabetic retinopathy and suboptimal HbA1c

This small pilot study provides preliminary evidence that visual feedback of personal retinal images may offer a practical educational strategy for clinicians in eye care services to improve diabetes outcomes in non-target compliant patients (Diabetic Medicine)



Monday, 2 September 2013

The Cardiovascular Safety of Diabetes Drugs

Insights from the Rosiglitazone Experience (New England Journal of Medicine)


Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo (New England Journal of Medicine)


Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes (New England Journal of Medicine)


ONGLYZA® (saxagliptin) achieves primary safety endpoint, demonstrating no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial

SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments (AstraZeneca)


Albuminuria and Cognitive Decline in People with Diabetes and Normal Renal Function

Persistent albuminuria and progressive albuminuria are associated with a decline in cognitive function in relatively young individuals with diabetes with unimpaired eGFR. These findings do not rule out the possibility of other processes causing cognitive decline (Clinical Journal of the American Society of Nephrology)

Sunday, 1 September 2013

Insulin resistance and bone strength. Findings from the study of midlife in the United States

Our study confirms that greater insulin resistance is related to lower femoral neck strength relative to load. Further, we note that hyperinsulinemia, rather than hyperglycemia, underlies this relationship. Although cross-sectional associations do not prove causality, our findings do suggest that insulin resistance and in particular, hyperinsulinemia, may negatively affect bone strength relative to load (Journal of Bone and Mineral Research)



The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model

The results of this study suggest that DAFNE is a cost-effective structured education programme for people with Type 1 diabetes and support its provision by the National Health Service in the UK (Diabetic Medicine)